For women who have survived cervical cancer, quitting smoking is one of the most important steps they can take to protect their long-term health. Yet it remains one of the hardest. A new study published in JAMA Network Open suggests that a personalised counselling programme may have finally found a way to change that.
Scientists at the University of California Los Angeles (UCLA) and Moffitt Cancer Center found that a programme called Motivation and Problem-Solving (MAPS) more than doubled quit rates among cervical cancer survivors compared to standard care. Cervical cancer survivors have some of the highest smoking rates of any cancer survivor group. The results mark a significant step forward.
Why Quitting Smoking After Cervical Cancer Is So Difficult
More than 30% of cervical cancer survivors continue to smoke after their diagnosis. This is despite clear evidence that smoking increases the risk of cancer recurrence, raises the likelihood of a second cancer, and reduces overall survival rates.
Many women struggle with quitting smoking after cervical cancer for both psychological and practical reasons. Many have low confidence in their ability to quit. Stress, emotional triggers, and ingrained habits all play a role. Some survivors simply do not know how directly smoking is tied to their cancer. Smoking is a key risk factor in the development and progression of cervical cancer, yet that link is still widely misunderstood.
“Many struggle with low motivation and confidence in quitting, stress and other triggers, and some do not realise how strongly smoking is linked to their cancer, which is why tailored support can make such a difference,” said Dr Tina Shih, senior author of the study and director of the Cancer Health Economics Research Programme at the UCLA Health Jonsson Comprehensive Cancer Center. “To date, there are very few programmes designed specifically for them.”
How the MAPS Programme Supports Smoking Cessation for Cervical Cancer Survivors
The clinical trial enrolled 194 women with a history of cervical intraepithelial neoplasia or cervical cancer who were current smokers. All participants received 12 weeks of nicotine replacement therapy, including patches and lozenges.
Half the group received standard support: self-help materials and a referral to a state quitline. The other half also received up to six personalised MAPS counselling sessions over 12 months. These sessions covered motivation, coping with cravings, stress management, relapse prevention, and broader lifestyle factors such as nutrition and physical activity.
The Results: Quit Rates for Cervical Cancer Survivors More Than Double
After 12 months, 26.5% of women in the MAPS group had successfully quit smoking. Only 12.5% in the standard care group did the same. That is more than double the quit rate, and the research team described the gap as both clinically meaningful and significant.
The cost picture was equally encouraging. The MAPS programme cost $523 per participant versus $389 for standard treatment. Yet it still delivered strong value. The programme cost just $921 for each additional person who quit smoking at 12 months. Researchers considered this cost-effective compared to other smoking cessation programmes at cancer centres. The probability it represented good value exceeded 90% at commonly accepted thresholds.
The picture shifted by the 18-month mark. Six months after counselling ended, quit rates in the MAPS group fell to 14.3%, compared to 12.5% in the standard group. The cost per quit rose to approximately $7,458 at this stage.
Engagement Makes the Difference
Women who attended four or more of the six counselling sessions showed considerably stronger and more lasting results. Researchers classified these as high-engagement participants. Among this group, cost-effectiveness stayed favourable even at 18 months.
For smoking cessation among cervical cancer survivors, consistency matters as much as the programme itself. The more committed a woman was to the process, the more durable her results.
What This Means for Cancer Centres
Generic, one-size-fits-all smoking cessation support falls short for many high-need groups. Cervical cancer survivors face a particular mix of health risks, social challenges, and psychological barriers. Targeted, sustained support produces far better outcomes than a standard quitline referral.
“The findings provide strong evidence that cancer centres that implement MAPS can achieve meaningful improvements in smoking cessation among cervical cancer survivors at a reasonable cost,” said Dr Shih. “More investment is needed to extend the duration of MAPS treatment and boost participant engagement to prevent relapse and sustain abstinence long-term.”
The National Cancer Institute funded the study. Xiaoyu Liu, a PhD candidate at the Department of Health Policy and Management at the UCLA Fielding School of Public Health, served as first author.
For women navigating life after a cervical cancer diagnosis, every positive health decision carries weight. The evidence around quitting smoking after cervical cancer is now clearer than ever, and so is the kind of support that can actually make it happen.
Leave a Reply